Refer a Patient Contact Us
Refer-a-Patient-hero-d

Refer a Patient

Refer a Patient to the PIONEER Clinical Trials

The PIONEER-1 and PIONEER-2 trials will take place in approximately 120 sites, across 3 continents. The countries involved in PIONEER-1 are: Australia, Canada, France, Germany, Italy, Poland, Spain and the United States. With the start of PIONEER-2, additional countries will be added.

 
 

If you are considering referring a patient to participate in the PIONEER trials it is important to refer them as early as possible. Please make sure the patients referred are adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss. The onset of visual loss symptoms must be within the previous 12 days before first administration of study treatment, for the patient to be eligible.

Refer a Patient to the PIONEER Clinical Trials

To refer a patient, learn more about the PIONEER trials or to locate a clinical study site, please fill up the contact form below.

This field is for validation purposes and should be left unchanged.
*Required Field

 

Oculis is not responsible for the content of any third-party sites or resources, and cannot guarantee the quality of information or support provided.

 

Privosegtor is an investigational drug candidate and has not been approved by the FDA. Safety and efficacy of Privosegtor for optic neuritis have not been established.